Pfizer / Bladder Cancer / C6001001

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of PF-08052667 as a Single Agent and in Combination Therapy in Participants 18 Years of Age and Older With Bladder Cancer (C6001001)
Principal Investigator
Headshot of Michael R Abern
Associate Professor of Urology
Protocol Number
IRB: PRO00119424
NCT: NCT07206225
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL